Ionis Pharmaceuticals Archives -

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus

GSK plans phase 3 for hepatitis B drug bepirovirsen, despite efficacy drop

https://pharmaphorum.com/news/gsk-plans-phase-3-for-hepatitis-b-drug-bepirovirsen-despite-efficacy-drop/

FDA delays decision on Biogen’s ALS hope tofersen

Phil Taylor amyotrophic lateral sclerosis, antisense oligonucleotides, Biogen, Ionis Pharmaceuticals, motor neuron disease, neurology 0 Comment

The FDA is planning to take an additional three months to review Biogen’s experimental therapy for amyotrophic lateral

FDA delays decision on Biogen’s ALS hope tofersen

https://pharmaphorum.com/news/fda-delays-decision-on-biogens-als-hope-tofersen/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ R&D

AZ and Ionis’ PCSK9 cholesterol drug will not move to phase 3

Phil Taylor Amgen, AstraZeneca, cholesterol, Ionis Pharmaceuticals, Leqvio, Novartis, PCSK9 inhibitors, Praluent, Regeneron, Repatha, Sanofi 0 Comment

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase

AZ and Ionis’ PCSK9 cholesterol drug will not move to phase 3

https://pharmaphorum.com/news/az-and-ionis-pcsk9-cholesterol-drug-will-not-move-to-phase-3/

News/ News/ R&D

Merck chases Bayer/Ionis with fast track for Factor XI drug

Phil Taylor anticoagulant, Bayer, dialysis, Ionis Pharmaceuticals, Merck & Co, nephrology, renal disease 0 Comment

The FDA has given a novel anticoagulant from Merck & Co a fast-track designation as a treatment for

Merck chases Bayer/Ionis with fast track for Factor XI drug

https://pharmaphorum.com/news/merck-chases-bayer-ionis-with-fast-track-for-factor-xi-drug/

News/ News/ R&D

Ionis antithrombotic with reduced bleed risk clears phase 2b study

Phil Taylor anticoagulant, Bayer, chronic kidney disease, dialysis, fesomersen, Ionis Pharmaceuticals 0 Comment

Patients with end-stage renal disease (ESRD) who are on dialysis often need to be treated with anticoagulants to

Ionis antithrombotic with reduced bleed risk clears phase 2b study

https://pharmaphorum.com/news/ionis-antithrombotic-with-reduced-bleed-risk-clears-phase-2b-study/

News/ News/ R&D

GSK hepatitis B hope bepirovirsen heads for phase 3 test

Phil Taylor antisense drugs, bepirovirsen, GlaxoSmithKline, hepatitis B, infectious disease, Ionis Pharmaceuticals 0 Comment

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a

GSK hepatitis B hope bepirovirsen heads for phase 3 test

https://pharmaphorum.com/news/gsk-hepatitis-b-hope-bepirovirsen-heads-for-phase-3-test/

News/ News/ R&D

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

Phil Taylor antisense oligonucleotides, AstraZeneca, ATTR amyloidosis, Ionis Pharmaceuticals, rare disease 0 Comment

Armed with new phase 3 data, AstraZeneca is preparing to file for regulatory approval of eplontersen, an antisense

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

https://pharmaphorum.com/news/az-preps-fda-filing-for-3-6bn-amyloidosis-drug-eplontersen/

Market Access/ News/ News/ News/ Sales and Marketing

Alnylam grabs FDA approval for its second amyloidosis therapy

Phil Taylor Alnylam Pharmaceuticals, Amvuttra, ATTR amyloidosis, Ionis Pharmaceuticals, Onpattro, regulatory approval, SOBI, Tegsedi 0 Comment

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis,

Alnylam grabs FDA approval for its second amyloidosis therapy

https://pharmaphorum.com/news/alnylam-grabs-fda-approval-for-its-second-amyloidosis-therapy/

News/ News/ R&D

New blow for ALS pipeline as Biogen and Ionis candidate fails Phase 1 trial

Eloise McLennan ALS, Biogen, clinical trials, Ionis Pharmaceuticals, pharma 0 Comment

Less than six months after the late-stage failure of tofersen, Biogen and Ionis have suffered further disappointment in

New blow for ALS pipeline as Biogen and Ionis candidate fails Phase 1 trial

https://pharmaphorum.com/news/new-blow-for-als-pipeline-as-biogen-and-ionis-candidate-fails-phase-1-trial/

Trending

Ionis Pharmaceuticals

Login